Ellex to launch Innovative New Ultrasound Technology at ASCRS in San Diego, California

Adelaide, Australia, 6 May 2019 – Ellex Medical Lasers Limited (ASX:ELX; OTCQX: ELXMY, ELXMF), a world leader in medical diagnosis and treatment of eye disease, today announced the market launch of the Company’s unique Eye Prime™ diagnostic ultrasound technology that is essential for evaluating pathology of the eye. FDA clearance was received on 12 April, 2019.

This proprietary diagnostic advance features a multifocal array of 6 focal points to provide the Doctor with crisp focus to improve image definition and clarity. The increased depth of field as well as real time dynamic imaging permits materially enhanced viewing of the fine and intricate structures inside the eye. These structures cannot be seen with currently available competitive offerings.

Dr Timothy Fuller, MD; Ocular Oncologist and Medical Retina Specialist, of Texas Retina Associates stated his impressions as follows; “Ellex’s Eye Prime technology greatly enhances my ability to follow intraocular tumours and more precisely analyse their characteristics.” He also went on to state; “… as a medical retina specialist, the improvements in resolution of the Eye Prime help me better diagnose and treat other retinal conditions including tears and vitreous detachments.”

Dr Inder Paul Singh, MD from the Eye Centres of Racine and Kenosha, Wisconsin highlighted a scientific case series illustrating real-time visualisation of vitreous floaters with the Eye Prime during laser treatment. The case series offered evidence as to the safety profile of this novel treatment approach. It also highlighted the superior clinical imaging ability of Eye Prime Technology.

Mr Ged Wallace, Chief Executive Officer of Ellex said: “I am pleased we have received FDA clearance for Eye Prime and launched this sophisticated diagnostic ultrasound innovation, in the key US market. Initial clinician feedback, touched on above, has been highly positive, and has reinforced our goal of delivering technologies that benefit our Medical clients and their deserving patients.”
ABOUT ELLEX

Ellex designs, develops, manufactures and sells innovative product that help eye surgeons around the world to effectively and efficiently treat eye disease. Ellex is a world leader in this field. Headquartered in Adelaide, Australia, Ellex has ophthalmic lasers and devices that treat glaucoma, retinal disease primarily caused by diabetes, secondary cataract and vitreous opacities, as well as age-related macular degeneration. Manufacturing is carried out in Adelaide, Australia and Fremont, California. Sales and service directly to eye surgeons is conducted via subsidiary offices in Minneapolis, Lyon, Berlin and Tokyo. A network of more than 50 distribution partners around the world services other markets.

For additional information about Ellex and its products, please visit www.ellex.com

For further information on Ellex please contact:

Ged Wallace
CEO
Ellex Medical Lasers Limited
3 Second Avenue, Mawson Lakes SA 5095
W +61 8 7074 8200
gwallace@ellex.com

Dr. Tom Duthy
Investor Relations & Corporate Development
Ellex Medical Lasers Limited
3 Second Avenue, Mawson Lakes SA 5095
M +61 402 493 727
tduthy@ellex.com

Maria Maieli
CFO & Company Secretary
Ellex Medical Lasers Limited
3 Second Avenue, Mawson Lakes SA 5095
W +61 8 7074 8200
mmaieli@ellex.com

Julia Maguire
Media Relations
The Capital Network
M: +61 419 815 386
julia@thecapitalnetwork.com.au